» Articles » PMID: 39230854

Comprehensive Review of Future Liver Remnant (FLR) Assessment and Hypertrophy Techniques Before Major Hepatectomy: How to Assess and Manage the FLR

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2024 Sep 4
PMID 39230854
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The regenerative capacities of the liver and improvements in surgical techniques have expanded the possibilities of resectability. Liver resection is often the only curative treatment for primary and secondary malignancies, despite the risk of post-hepatectomy liver failure (PHLF). This serious complication (with a 50% mortality rate) can be avoided by better assessment of liver volume and function of the future liver remnant (FLR).

Objective: The aim of this review was to understand and assess clinical, biological, and imaging predictors of PHLF risk, as well as the various hypertrophy techniques, to achieve an adequate FLR before hepatectomy.

Method: We reviewed the state of the art in liver regeneration and FLR hypertrophy techniques.

Results: The use of new biological scores (such as the aspartate aminotransferase/platelet ratio index + albumin-bilirubin [APRI+ALBI] score), concurrent utilization of Tc-mebrofenin scintigraphy (HBS), or dynamic hepatocyte contrast-enhanced MRI (DHCE-MRI) for liver volumetry helps predict the risk of PHLF. Besides portal vein embolization, there are other FLR optimization techniques that have their indications in case of risk of failure (e.g., associating liver partition and portal vein ligation for staged hepatectomy, liver venous deprivation) or in specific situations (transarterial radioembolization).

Conclusion: There is a need to standardize volumetry and function measurement techniques, as well as FLR hypertrophy techniques, to limit the risk of PHLF.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
de Ridder J, de Wilt J, Simmer F, Overbeek L, Lemmens V, Nagtegaal I . Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget. 2016; 7(34):55368-55376. PMC: 5342423. DOI: 10.18632/oncotarget.10552. View

3.
Benson A, DAngelica M, Abbott D, Anaya D, Anders R, Are C . Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(5):541-565. DOI: 10.6004/jnccn.2021.0022. View

4.
Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw. 2020; 18(7):806-815. DOI: 10.6004/jnccn.2020.0032. View

5.
Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K . One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003; 138(11):1198-206. DOI: 10.1001/archsurg.138.11.1198. View